Postintubation Decline in Oxygen Saturation Index Predicts Mortality in COVID-19: A Retrospective Pilot Study

Ala Nozari,1 Shivali Mukerji,1 Molly Vora,1 Alfonso Garcia,1 Alyssa Park,1 Nicholas Flores,1 Robert Canelli,1 Gerardo Rodriguez,1,3 Riccardo Pinciroli,2 Alexander Nagrebetsky,2 Rafael Ortega,1 and Sadeq A. Quraishi3

1Department of Anesthesiology, Boston Medical Center, Boston, MA, USA
2Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
3Department of Anesthesiology, Tufts Medical Center, Boston, MA, USA

Correspondence should be addressed to Ala Nozari; ala.nozari@bmc.org

Received 11 December 2020; Accepted 11 May 2021; Published 26 May 2021

Background. Acute respiratory failure from COVID-19 pneumonia is a major cause of death after SARS-CoV-2 infection. We investigated whether PaO2/FiO2, oxygenation index (OI), SpO2/FiO2, and oxygen saturation index (OSI), commonly used to assess the severity of acute respiratory distress syndrome (ARDS), can predict mortality in mechanically ventilated COVID-19 patients.

Methods. In this single-centered retrospective pilot study, we enrolled 68 critically ill mechanically ventilated adult patients with confirmed COVID-19. Physiological variables were recorded on the day of intubation (day 0) and postintubation days 3 and 7. The association between physiological parameters, PaO2/FiO2, OI, SpO2/FiO2, and OSI with mortality was assessed using multiple variable logistic regression analysis. Receiver operating characteristic analysis was conducted to evaluate the performance of the predictive models.

Results. The ARDS severity indices were not statistically different on the day of intubation, suggesting similar baseline conditions in nonsurviving and surviving patients. However, these indices were significantly worse in the nonsurviving as compared to surviving patients on postintubation days 3 and 7. On intubation day 3, PaO2/FiO2 was 101.0 (61.4) in nonsurviving patients vs. 140.2 (109.6) in surviving patients, p = 0.004, and on day 7 106.3 (94.2) vs. 178.0 (69.3), p < 0.001. OI was 135.0 (129.7) in nonsurviving vs. 84.8 (86.1) in surviving patients (p = 0.003) on day 3 and 150.0 (118.4) vs. 61.5 (46.7) (p < 0.001) on day 7. OSI was 12.0 (11.7) vs. 8.0 (10.0) (p = 0.006) on day 3 and 14.7 (13.2) vs. 6.5 (5.4) (p < 0.001) on day 7. Similarly, SpO2/FiO2 was 130 (90) vs. 210 (90) (p = 0.003) on day 3 and 130 (90) vs. 230 (50) (p < 0.001) on day 7, while OSI was 12.0 (11.7) vs. 8.0 (10.0) (p = 0.006) on day 3 and 14.7 (13.2) vs. 6.5 (5.4) (p < 0.001) on day 7 in the nonsurviving and surviving patients, respectively. All measures were independently associated with hospital mortality, with significantly greater odds ratios observed on day 7. The area under the receiver operating characteristic curve (AUC) for mortality prediction was greatest on intubation day 7 (AUC = 0.775, 0.808, and 0.828 for PaO2/FiO2, OI, SpO2/FiO2, and OSI, respectively). Conclusions. Decline in oxygenation indices after intubation is predictive of mortality in COVID-19 patients. This time window is critical to the outcome of these patients and a possible target for future interventions. Future large-scale studies to confirm the prognostic value of the indices in COVID-19 patients are warranted.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is known to invade the pulmonary alveolar epithelial cells primarily [1]. While most infected patients have mild to no symptoms, some develop acute hypoxemic respiratory failure that can progress to multiorgan failure and death [2]. Early studies on critically ill patients with coronavirus disease 2019 (COVID-19) revealed long mechanical ventilation times, with one study among New York City patients reporting a median of 18 days and others up to 59 days of mechanical ventilation [3, 4]. Even patients with milder
form of the disease may require prolonged respiratory support; one study reported an average of 14.6 days of mechanical ventilation in patients who survived COVID-19 pneumonia [4]. It is important to identify patients who are at greatest risk of major complications so that appropriate treatments are provided earlier in the disease process. This will also aid providers in discussing compassionate palliative care and end of life decisions with the patients and their families. As such, a better understanding of the prognosis and course of the severe coronavirus disease 2019 (COVID-19) is critical for resource allocation and medical management.

An important pathological feature of the lungs obtained on autopsy from patients with COVID-19 is the presence of diffuse alveolar damage and widespread signs of thrombosis, similar to findings in patients with acute respiratory distress syndrome (ARDS) [5, 6]. The clinical presentation and respiratory mechanics of COVID-19 pneumonia are also largely comparable to other forms of ARDS, although a less aggressive “normal compliance” type of COVID-19 has been described [7]. Accordingly, clinicians have applied physiological measures of ARDS severity to COVID-19 patients, without any evidence to support their prognostic values. One important example is the ratio of arterial oxygen tension (PaO₂) to fraction of inspired oxygen (FiO₂), or the PaO₂/FiO₂ ratio. Besides classifying the severity of ARDS, the PaO₂/FiO₂ ratio also has prognostic value, being associated with mortality according to the ARDS Definition Task Force [8]. Mild ARDS (PaO₂/FiO₂ 200–300) is associated with 27% mortality, while moderate (PaO₂/FiO₂ 100–200) and severe (PaO₂/FiO₂ < 100) ARDS are associated with 32% and 45% mortality rates, respectively.

Another physiological index used to stratify the severity of pulmonary dysfunction in ARDS is the product of the mean alveolar pressure (MAP) and the reciprocal of pulmonary dysfunction in ARDS is the product of the PaO₂/FiO₂ ratio also has prognostic value, being associated with mortality according to the ARDS Definition Task Force [8]. Mild ARDS (PaO₂/FiO₂ 200–300) is associated with 27% mortality, while moderate (PaO₂/FiO₂ 100–200) and severe (PaO₂/FiO₂ < 100) ARDS are associated with 32% and 45% mortality rates, respectively.

Although the clinical and prognostic values of the above oxygenation indices are well established in ARDS, they have yet not been validated in COVID-19 patients. We conducted a retrospective pilot study to explore the association of OI and OSI with survival in a subgroup of COVID-19 patients with significant lung injury and acute respiratory failure requiring mechanical ventilation. Additionally, studying survivors compared to nonsurvivors, we assessed how oxygenation varied over the first 7 days following intubation to establish the value of PaO₂/FiO₂, OI, SpO₂/FiO₂, and OSI as early predictors of outcome. We hypothesized that oxygenation indices are better in COVID-19 survivors as compared to nonsurvivors upon intubation and will continue to improve as patients progressively recover.

2. Methods

2.1. Study Design and Population. The study was conducted at the Boston Medical Center, the largest safety-net hospital in Boston and a level 1 academic trauma center. The study protocol was approved by the Boston Medical Center Institutional Review Board. The requirement for written informed consent was waived given the retrospective nature of the study. All consecutive adult patients with confirmed COVID-19 infection who were admitted to the medical and surgical intensive care units between 3/1/2020 and 6/30/2020 for acute hypoxic respiratory failure and required mechanical ventilation were enrolled in the study. Patients who were admitted for reasons other than respiratory failure were excluded. Patients who were discharged to another facility, and for whom the primary outcome (survivor vs non-survivor) was unknown, were also excluded. We defined day 0 as the day of intubation and initiation of mechanical ventilation.

All patients met the Berlin criteria for ARDS and were treated according to a standard institution-wide, lung-protective ventilation protocol. Specifically, mechanical ventilation was managed by the clinical team of intensivists and respiratory therapists according to the ARDSnet recommendations for titration of PEEP/FiO₂ and to maintain a plateau pressure of <30 cm H₂O. Contempory national guidelines were followed for the management of COVID-19. It included empiric antibiotic treatment with azithromycin, administration of hydroxychloroquine, and immunomodulation with the interleukin-6 receptor inhibitor tocilizumab, interleukin-1 receptor antagonist anakinra, the antiviral agent remdesivir, and anticoagulation, when appropriate. Prone positioning, neuromuscular blocking agents, and inhaled nitric oxide were also employed at the discretion of the treating clinicians.

2.2. Data Collection. Demographic data, medical history, preadmission medications, and diagnoses were extracted from each enrolled patient’s electronic medical record. Clinical data were also extracted from the electronic medical records until extubation or death, whichever occurred first. Data included patients’ vital signs, laboratory parameters, and clinical imaging including chest X-rays. Ventilator settings and arterial blood gas (ABG) parameters were recorded at a daily reference time of approximately 18:00. Special attention was paid to avoiding data collection within 30 minutes of respiratory interventions including suctioning of the endotracheal tube, recruitment maneuvers, bronchoscopies, and acute changes in ventilator settings. Calculated variables included the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) score, Charlson Comorbidity Index (CCI), respiratory compliance (Crs), PaO₂/FiO₂, SpO₂/FiO₂, OI, and OSI. OI was calculated as (mean airway...
pressure $\times$ FiO$_2$×100)/PaO$_2$, and OSI was calculated as (mean airway pressure $\times$ FiO$_2$×100)/SpO$_2$. Higher OI and OSI values indicate worse oxygenation [11]. Anonymized records were entered into a secure cloud-based data entry online platform (StudyTRAX, Macon, GA) and subsequently extracted for analysis.

2.3. Statistical Analysis. The primary outcome variable was death before hospital discharge; therefore, all patients were categorized as survivors or nonsurvivors and followed until death or hospital discharge. Because this was a pilot study, a sample size sufficient to assess the feasibility of the retrospective methods was required as opposed to the global COVID-19 patients. Categorical variables were presented as counts and percentages. Continuous variables were presented as mean± standard deviation (SD) or median with interquartile range (IQR) and compared between groups (survivors vs nonsurvivors) using t-tests or Mann–Whitney U/log-rank tests, respectively. Categorical variables were presented as proportions and compared between groups using chi-squared tests. Independent-samples Kruskal–Wallis test was used to compare the distribution of Crs, PaO$_2$/FiO$_2$, SpO$_2$/FiO$_2$, OI, and OSI in surviving and nonsurviving patients, with the Bonferroni correction to preserve the overall type I error at 0.05.

Related-samples Wilcoxon signed rank test was used to compare change in respiratory indices over time. Multivariable logistic regression modeling was used to assess the association between Crs, PaO$_2$/FiO$_2$, SpO$_2$/FiO$_2$, OI, and OSI on postintubation days 0, 3, and 7 and in-hospital mortality, adjusting for age, CCI, and sex. Receiver operating characteristic curves were used to analyze prognostic value for mortality for PaO$_2$/FiO$_2$, SpO$_2$/FiO$_2$, OI, and OSI on days 0, 3, and 7. Statistical analyses were completed using SPSS Statistics 26 (IBM Corporation, Chicago, IL), SAS (SAS Institute, Cary, NC), and a two-sided significance level of 0.05 was used for statistical inference.

3. Results

A total of 498 patients with confirmed COVID-19 pneumonia were admitted to our hospital between March 1, 2020, and June 30, 2020, of whom 119 required ICU admission and 68 met inclusion criteria for this study (Figure 1). These patients had moderate to severe ARDS characterized by a marked impairment in oxygenation with a median PaO$_2$/FiO$_2$ of 118 [IQR 103.3] in survivors and 105 [IQR 78.1] in nonsurvivors, low compliance (median Crs 18.8 [IQR 18.5] and 16.8 [IQR 7.8], respectively), and bilateral opacities on their chest imaging, which was not different between groups. Thirty-two (47%) patients were successfully extubated and discharged from the hospital, while 36 (53%) expired within 17 [IQR 9] days after hospital admission.

Demographic characteristics and clinical data for each group of patients are summarized in Table 1. Most patients had a variety of comorbid conditions, with the common diagnoses being diabetes mellitus (39% in survivors and 74% in nonsurvivors), coronary artery disease with a history of myocardial infarction (3% in survivors and 28.6% in nonsurvivors), congestive heart failure (12.1% in survivors and 25.7% in nonsurvivors), and cerebrovascular disease and chronic obstructive pulmonary disease. Advanced age, CCI score, history of MI, and preexisting diabetes were associated with an increased risk of mortality, while other clinical characteristics on ICU admission were not. Average ICU length of stay was 13.7 (7.7) in survivors and 15.8 (8.5) in nonsurvivors ($p = 0.365$) and hospital length of stay was 21.6 (10.2) and 16.9 (8.7), $p = 0.086$, respectively.

Crs, PaO$_2$/FiO$_2$, SpO$_2$/FiO$_2$, OI, and OSI were not significantly different between survivors and nonsurvivors on the day of intubation or day 0 (Table 2). PaO$_2$/FiO$_2$ as well as SpO$_2$/FiO$_2$ improved in survivors on day 3 (from a PaO$_2$/FiO$_2$ of 118.1 [103.2] to 140.2 [109.5], $p = 0.029$, and a SpO$_2$/FiO$_2$ of 150 (80) to 210 (90), $p = 0.002$), but not in the nonsurviving patients (from 105.0 (78.1) to 101.0 (61.4), $p = 0.245$, and from 120 (70) to 130 (90), $p = 0.338$, respectively). On postintubation day 7, the PaO$_2$/FiO$_2$ had increased to 178 (69.3) in survivors, which was markedly better than their PaO$_2$/FiO$_2$ ratio on the day of intubation ($p = 0.01$). Similarly, SpO$_2$/FiO$_2$ improved to 230 in survivors ($p < 0.001$ versus day 0), but not in nonsurvivors. OI and OSI followed the same trend and continued to worsen (increase) after intubation in the nonsurviving patients. OI increased from 116.0 (90.8) on day 0 to 150.0 (118.4) on day 7, $p = 0.039$ while it improved (from 82.9 (95.3) to 61.5 (46.7), $p = 0.013$) in survivors. OSI increased from 12.2 (9.2) on day 0 to 14.7 (13.2) on day 7 in nonsurvivors ($p = 0.035$) but decreased (improved) (in survivors) from 10.9 (7.8) to 6.5 (5.4), $p = 0.002$.

On postintubation day 3, the Crs and PaO$_2$/FiO$_2$ and SpO$_2$/FiO$_2$ were higher and OI and OSI were lower in survivors as compared to nonsurvivors (Table 2). The group difference in these pulmonary variables was even greater on day 7 ($p = 0.007$ for Crs and <0.001 for all oxygenation indices), with markedly better (lower) OI and OSI in the survivors as compared to nonsurvivors.

In a multivariate logistic regression model, Crs, PaO$_2$/FiO$_2$, SpO$_2$/FiO$_2$, OI, and OSI on intubation days 3 and 7, respectively, were associated with death when adjusted for age, CCI, and sex (Table 3). Adjusted OR per 10 mmHg decrease in PaO$_2$/FiO$_2$ were 1.116 (95% CI: 1.020–1.231), $p = 0.0229$, and 1.172 (95% CI: 1.051–1.318), $p = 0.0045$; adjusted OR per 10 cm H$_2$O/mmHg increase in OSI were 1.088 (95% CI: 1.013–1.164), $p = 0.033$; and 1.344 (95% CI: 1.061–1.698), $p < 0.01$; and adjusted OR per cm H$_2$O increase in OSI were 1.088 (95% CI: 1.007–1.177), $p = 0.033$, and 1.346 (95% CI: 1.146–1.581), $p < 0.001$, on days 3 and 7 after intubation, respectively.

We tested the individual performance of OI, OSI, PaO$_2$/FiO$_2$, and SpO$_2$/FiO$_2$ on intubation days 0, 3, and 7 to predict hospital mortality by calculating the AUC of the receiver operating characteristic curves (Figure 2 and Table 4). While all indices had only moderate performance for mortality prediction on the intubation day (AUC ranging from 0.544 and 0.605), they were significant predictors of...
mortality on postintubation days 3 and 7 with excellent performance of both the arterial blood gas-dependent variables and the noninvasive pulse oximeter-derived indices: AUC was 0.684 (95% CI: 0.546–0.822) and 0.808 (95% CI: 0.697–0.919) on days 3 and 7 for OI and 0.655 (95% CI: 0.514–0.797) and 0.828 (95% CI: 0.724–0.932) for OSI. Given the report of a better performance of OI and OSI in young patients, we also analyzed the receiver operating characteristic (ROC) curve for patients younger than 60 years of age to determine if discrimination was improved. Although the analysis was limited by the lower number of these patients, the AUC of the ROC curves were even better in this group of younger patients: AUC for OI was 0.802 (95% CI: 0.604–1.000) and 1.000 (95% CI: 1.000–1.000) and for OSI 0.733 (95% CI: 0.517–0.949) and 1.000 (95% CI: 1.000–1.000) on days 3 and 7, respectively.

4. Discussion

In this retrospective observational pilot study of 68 critically ill patients with confirmed COVID-19 pneumonia, we present evidence to suggest that PaO2/FiO2, SpO2/FiO2, OI, and OSI can serve as predictors of mortality after intubation. While difference in oxygenation was marginal and did not reach clinical or statistical significance on the day of intubation, suggesting comparable baseline characteristics in survivors and nonsurvivors, survivors rapidly distinguished themselves with a higher PaO2/FiO2 and SpO2/FiO2 and lower OI and OSI within 3 days. Lung compliance followed the same trend and was significantly higher in survivors on days 3 and 7 with no significant difference between the two groups on day 0.

4.1. The Importance of Prognostication in the Critically Ill COVID-19 Patients. In patients with COVID-19 infection, it is particularly difficult to provide accurate prognostic information, as the case fatality rate has been quite variable ranging from 0.7% in Germany to about 10% in Italy [16]. Decisions about goals of care and life-sustaining treatments are made by incorporating available medical and prognostic data with the preferences of each patient and his or her surrogate. This process depends on the clinician’s ability to provide understandable and accurate prognostic information. Existing mortality data must be considered for each specific condition and appropriately applied to the individual patient. Mortality rates between 24% and 67% have been reported in patients requiring hospital admission [17, 18]. COVID-19 patients who require ICU admission and intubation have a particularly high mortality rate, but besides preexisting risk factors such as age, cardiovascular disease, diabetes, and COPD, no clinical prognostic tools have been validated for identifying those at greater risk of death [19, 20]. The findings reported herein confirm the prognostic value of PaO2/FiO2 and OI in these patients and can therefore serve as an important tool to guide therapeutic management and goals of care discussions and decision-making conversations for COVID-19 patients with...
respiratory failure. However, clinicians should consider the dynamic nature of the oxygenation indices, and the need to wait at least 3 days after intubation for a more reliable prognostication. These metrics can then serve as additional data points to inform resource allocation in crisis scenarios when access to therapeutic measures is limited or the number of critically ill COVID-19 patients overwhelms the hospitals and health providers.

4.2. The Importance of Respiratory Mechanics. Although previous studies have established the importance of oxygenation indices and lung mechanics in patients with ARDS, these important findings have not been validated in COVID-19 patients. The Berlin definition of ARDS uses the PaO2/FiO2 ratio as the primary measure of ARDS severity, but some studies have failed to validate it as an independent predictor of mortality [21, 22]. It is argued that the outcome in ARDS is affected not only by the degree of oxygenation impairment but also by the mechanical properties of the lungs and the impact of ventilator-induced lung injury (VILI). Integrating both airway pressure and oxygenation into a single index, OI and OSI, might be more powerful predictors of death in ARDS patients [23, 24]. This is of particular importance in COVID-19 pneumonia, given the reported heterogeneity in Crs [7], and respiratory mechanics were therefore expected to have an even greater prognostic relevance. Nevertheless, our results showed that, despite differences in compliance between survivors and nonsurvivors on intubation days 3 and 7, PaO2/FiO2 and SpO2/FiO2 remain as powerful as OI and OSI in predicting mortality, possibly suggesting that the primary determinant of mortality is the degree of oxygenation impairment as opposed to respiratory mechanics.

4.3. Temporal Evolution of Oxygenation Indices in Intubated COVID-19 Patients. As stated earlier, we were surprised to find that despite differences in baseline clinical characteristics, the ARDS indices (PaO2/FiO2, OI, and OSI) did not significantly differ between survivors and nonsurvivors on intubation day 0. These findings differ from previous studies of the oxygenation indices, which reported their prognostic power at the time of ARDS diagnosis [15, 25]. It is plausible that, given the initially comparable oxygenation indices in our COVID-19 patients, the pulmonary disease burden may not have been significantly different between the survivor and nonsurvivor groups at the time of intubation. However, over the course of only three days, nonsurvivors were clearly distinguished with significantly worse oxygenation indices as compared to survivors, suggesting significant progression in their pulmonary disease and lung injury. It is of course impossible to determine the cause of the observed divergence in disease progression, but this finding may indicate a time window that is critical to the outcome of intubated COVID-19 patients and potentially a target for future interventions.

4.4. The Simplicity of Noninvasive Pulse Oximetry for Assessment of the ARDS Severity. The importance of a continuous assessment of oxygenation is well recognized. Still, it is often limited to recording oxygen saturation or intermittently reviewing blood gas parameters, both of which are critically dependent on the fraction of inspired oxygen. By calculating the PaO2/FiO2 and SpO2/FiO2 ratios as well as the oxygenation and oxygen saturation indices, our study extends the role of such physiological indices as relevant estimates of disease severity. Also, it validates these measurements as valuable prognostic tools in critically ill COVID-19 patients. Importantly, we show that noninvasive measures, such as SpO2/FiO2 and OSI, derived from pulse oximetry, are equally predictive of outcome when compared to those obtained from arterial blood gas values.

### Table 1: Clinical characteristics of the COVID-19 patients with acute hypoxic respiratory failure requiring intubation.

| Characteristic                          | Survivors (mean ± SD) | Nonsurvivors (mean ± SD) | p       |
|-----------------------------------------|-----------------------|--------------------------|---------|
| Age in years (SD)                       | 58.1 (16.3)           | 68.3 (10.8)              | 0.0036  |
| Gender                                  |                       |                          |         |
| Female (n (%))                          | 7 (21.21%)            | 15 (42.86%)             | 0.0565  |
| Male (n (%))                            | 26 (78.79%)           | 20 (57.14%)             | 0.0565  |
| Race                                    |                       |                          |         |
| White (n (%))                           | 9 (31.03%)            | 7 (20.59%)               | 0.6544  |
| African American (n (%))                | 14 (48.28%)           | 18 (52.94%)              | 0.6544  |
| Asian (n (%))                           | 0 (0%)                | 1 (2.94%)                | 0.6544  |
| Others (n (%))                          | 0 (0%)                | 1 (2.94%)                | 0.6544  |
| Unknown (n (%))                         | 6 (20.69%)            | 7 (20.59%)               | 0.6544  |
| Ethnicity                               |                       |                          |         |
| Hispanic                                | 14 (42.42%)           | 9 (25.71%)               | 0.1455  |
| Non-Hispanic                            | 19 (57.58%)           | 26 (74.29%)              | 0.1455  |
| BMI                                     | 31.89 (8.43)          | 33.48 (7.66)             | 0.4731  |
| APACHE II                               | 21.2 (6.8)            | 20.3 (10.5)              | 0.8314  |
| Charlson comorbidity index              | 3.5 (2.9)             | 5.9 (2.2)                | 0.0004  |
| Myocardial infarction                   | 1 (3.03%)             | 10 (28.57%)              | 0.0043  |
| Congestive heart failure                | 4 (12.12%)            | 9 (25.71%)               | 0.1543  |
| Peripheral vascular disease             | 3 (9.09%)             | 5 (14.29%)               | 0.5064  |
| Cerebrovascular disease                 | 5 (15.15%)            | 4 (11.43%)               | 0.6507  |
| Chronic obstructive lung disease        | 3 (9.09%)             | 6 (17.14%)               | 0.3275  |
| Liver disease                           | 1 (3.03%)             | 0 (0%)                   | 0.4821  |
| Chronic kidney disease                  | 2 (6.06%)             | 10 (28.57%)              | 0.0149  |
| Diabetes mellitus                       | 13 (39.39%)           | 26 (74.29%)              | 0.0036  |
| Laboratory parameters                   |                       |                          |         |
| C-reactive protein (mg/dL)              | 119.4 (121.0)         | 113.8 (110.9)            | 0.8532  |
| D-dimer (mg/mL)                         | 1.6 (2.4)             | 3.2 (6.8)                | 0.2059  |
| Hemoglobin (g/dL)                       | 12.1 (2.2)            | 11.9 (1.7)               | 0.7908  |
| Procalcitonin (ng/mL)                   | 1.2 (3.1)             | 3.0 (5.8)                | 0.1084  |
| Creatinine (mg/dL)                      | 1.2 (1.3)             | 1.9 (1.9)                | 0.0734  |
| Respiratory parameters                  |                       |                          |         |
| PEEP (cm H2O)                           | 10.2 (3.3)            | 11.8 (3.1)               | 0.045   |
| FiO2 (%)                                | 69.3 (21.7)           | 73.6 (21.1)              | 0.4113  |
| MAP (cm H2O)                            | 14.3 (3.5)            | 16.5 (3.7)               | 0.0183  |
| Tidal volume (ml)                       | 446.3 (417.7)         | 420.5 (65.7)             | 0.0565  |
| Days ventilated                         | 13.9 (9.1)            | 14.7 (8.3)               | 0.7304  |
| ICU length of stay (days)               | 13.7 (7.7)            | 15.8 (8.5)               | 0.3652  |
| Hospital length of stay (days)          | 21.6 (10.2)           | 16.9 (8.7)               | 0.0859  |

Values are presented as mean (%), mean (SD) when normally distributed, or median (IQR).
Moreover, SpO2/FiO2 is as powerful a predictor as OSI, obviating the need to routinely incorporate pulmonary mechanics in the assessment of the severity of respiratory failure in COVID-19 patients. The effects of therapeutic interventions, as well as prognostication and identification of patients who will benefit the most from continued mechanical ventilation and ICU care, can all be guided by a simple calculation of the SpO2/FiO2.

### 4.5. Use of SpO2/FiO2 to Guide Therapeutic Approach to Intubated COVID-19 Patients
While the pathophysiology of ARDS has been extensively studied, its treatment is currently mostly based on supportive intensive care and prevention of VILI. Mortality from the disease ranges from 30 to 60% [11]. The COVID-19-related lung injury is no exception being, at best, only marginally controlled by the currently accepted standard treatments, including antibiotic, antiviral, and immunomodulatory agents. Lung-protective ventilation using small tidal volumes with permissive hypercapnia remains the cornerstone of ARDS management, as it facilitates the goal of minimizing VILI. Lung recruitment strategies, careful optimization of the positive end expiratory pressure (PEEP), pulmonary vasodilators, and prone positioning are also employed to optimize ventilation distribution as well as ventilation-perfusion matching in COVID-19 patients [26]. Evidence to support novel antiviral and anti-inflammatory therapies continues to evolve, as does the data on convalescent plasma, immune globulin, and monoclonal antibodies. The therapeutic and respiratory effects of these treatments might be guided by their impact on pulmonary compliance and oxygenation indices, including a simple calculation of SpO2/FiO2.

### 4.6. Strengths and Limitations of the Study
The strengths of this study include the unique burden of COVID-19 in the

| Intubation day | Survivors | Nonsurvivors | p | Survivors | Nonsurvivors | p |
|----------------|-----------|--------------|---|-----------|--------------|---|
| **Lung compliance** | | | | | | |
| Day 0 | 18.8 (IQR 18.5) | 16.8 (IQR 7.8) | 0.105 | | | |
| Day 3 | 19.4 (IQR 22.4) | 14.6 (IQR 7.2) | 0.014 | | | |
| Day 7 | 21.5 (IQR 25.3) | 15.8 (IQR 9.9) | 0.007 | | | |
| **PaO2/FiO2 ratio** | | | | | | |
| Day 0 | 118.1 (IQR 103.3) | 105.0 (IQR 78.1) | 0.432 | | | |
| Day 3 | 140.2 (IQR 109.6) | 101.0 (IQR 61.4) | 0.004 | | | |
| Day 7 | 178.0 (IQR 69.3) | 106.3 (IQR 94.2) | <0.001 | | | |
| **Oxygenation index** | | | | | | |
| Day 0 | 82.9 (IQR 95.3) | 116.0 (IQR 90.8) | 0.165 | | | |
| Day 3 | 84.8 (IQR 86.1) | 135.0 (IQR 129.7) | 0.003 | | | |
| Day 7 | 61.5 (IQR 46.7) | 150.0 (IQR 118.4) | <0.001 | | | |
| **SpO2/FiO2 ratio** | | | | | | |
| Day 0 | 150.0 (IQR 80) | 120.0 (IQR 70) | 0.217 | | | |
| Day 3 | 210.0 (IQR 90) | 130.0 (IQR 90) | 0.003 | | | |
| Day 7 | 230.0 (IQR 50) | 130.0 (IQR 90) | <0.001 | | | |
| **Oxygen saturation index** | | | | | | |
| Day 0 | 10.9 (IQR 7.8) | 12.2 (IQR 9.2) | 0.052 | | | |
| Day 3 | 8.0 (IQR 10.0) | 12.0 (IQR 11.7) | 0.006 | | | |
| Day 7 | 6.5 (IQR 5.4) | 14.7 (IQR 13.2) | <0.001 | | | |

Data are presented as median (interquartile range).

### Table 3: Unadjusted and multivariate adjusted odds ratio of death for Crs, PaO2/FiO2, OI, SpO2/FiO2, and OSI.

| Day 0 | Unadjusted OR (95% CI) | Multivariate OR * (95% CI) | p val (unadj) | p val (adj) |
|-------|------------------------|----------------------------|---------------|-------------|
| Crs (per 10 ml/cm H2O decrease) | 1.644 (0.951, 2.839) | 1.318 (0.960, 2.456) | 0.0737 | 0.383 |
| PaO2/FiO2 (per 10 mmHg decrease) | 1.020 (0.951, 1.083) | 1.010 (0.942, 1.083) | 0.6193 | 0.8289 |
| OI (per 10 cm H2O/mmHg increase) | 1.041 (0.961, 1.116) | 1.030 (0.942, 1.12) | 0.3593 | 0.5039 |
| SpO2/FiO2 (per 10 unit decrease) | 1.051 (0.961, 1.161) | 1.062 (0.961, 1.172) | 0.3908 | 0.2285 |
| OSI (per cm H2O increase) | 1.107 (0.996, 1.230) | 1.119 (0.996, 1.258) | 0.0587 | 0.0588 |

| Day 3 | Unadjusted OR (95% CI) | Multivariate OR * (95% CI) | p val (unadj) | p val (adj) |
|-------|------------------------|----------------------------|---------------|-------------|
| Crs (per 10 ml/cm H2O decrease) | 1.930 (1.149, 3.219) | 1.708 (1.00, 2.943) | 0.0124 | 0.0512 |
| PaO2/FiO2 (per 10 mmHg decrease) | 1.104 (1.020, 1.207) | 1.116 (1.020, 1.231) | 0.0164 | 0.0229 |
| OI (per 10 cm H2O/mmHg increase) | 1.093 (1.020, 1.207) | 1.0937 (1.010, 1.184) | 0.0142 | 0.0242 |
| SpO2/FiO2 (per 10 mmHg decrease) | 1.138 (1.041, 1.243) | 1.116 (1.020, 1.231) | 0.0048 | 0.0235 |
| OSI (per cm H2O increase) | 1.092 (1.017, 1.173) | 1.088 (1.007, 1.177) | 0.0156 | 0.0333 |

| Day 7 | Unadjusted OR (95% CI) | Multivariate OR * (95% CI) | p val (unadj) | p val (adj) |
|-------|------------------------|----------------------------|---------------|-------------|
| Crs (per 10 ml/cm H2O decrease) | 2.119 (1.207, 3.772) | 2.004 (1.072, 3.740) | 0.0094 | 0.0282 |
| PaO2/FiO2 (per 10 mmHg decrease) | 1.149 (1.041, 1.268) | 1.172 (1.051, 1.318) | 0.0053 | 0.0045 |
| OI (per 10 cm H2O/mmHg increase) | 1.267 (1.105, 1.452) | 1.357 (1.138, 1.613) | 0.0006 | 0.0006 |
| SpO2/FiO2 (per 10 unit decrease) | 1.293 (1.138, 1.466) | 1.344 (1.161, 1.568) | <0.0001 | 0.0001 |
| OSI (per cm H2O increase) | 1.275 (1.120, 1.451) | 1.346 (1.346, 1.581) | 0.0002 | 0.0003 |
ICU level care at our institution and the uniformity of care provided to these patients. According to the estimates from our admissions office, our institution shouldered a disproportionate number of admissions within our community, with our inpatient census reaching 70% suffering from COVID-19; our ICU census reached 90% of patients with confirmed COVID-19 pneumonia. Though this study has several limitations including a small size and a high mortality rate, the sample size was sufficient to demonstrate the statistically significant and clinically meaningful associations. Unfortunately, given the retrospective nature of this pilot study as well as the limited number of patients, we are unable to demonstrate the clinical significance of our findings. Larger prospective studies are needed to validate our findings and confirm its clinical significance. Our data are also part of a larger dataset collected in several participating academic institutions in Boston and beyond. We aim to validate our findings in this larger cohort.


**Table 4: Comparison of areas under the receiver operating characteristic curve for discrimination of hospital survival.**

| Day 0       | AUC   | 95% CI    |
|-------------|-------|-----------|
| Lung compliance | 0.584 | (0.421, 0.748) |
| PaO₂/FiO₂    | 0.544 | (0.394, 0.694) |
| Oxygenation index | 0.569 | (0.417, 0.721) |
| SpO₂/FiO₂    | 0.573 | (0.426, 0.719) |
| Oxygen saturation index | 0.605 | (0.461, 0.750) |

| Day 3       | AUC   | 95% CI    |
|-------------|-------|-----------|
| Lung compliance | 0.625 | (0.459, 0.790) |
| PaO₂/FiO₂    | 0.708 | (0.573, 0.843) |
| Oxygenation index | 0.684 | (0.546, 0.822) |
| SpO₂/FiO₂    | 0.674 | (0.532, 0.816) |
| Oxygen saturation index | 0.655 | (0.514, 0.797) |

| Day 7       | AUC   | 95% CI    |
|-------------|-------|-----------|
| Lung compliance | 0.680 | (0.525, 0.835) |
| PaO₂/FiO₂    | 0.775 | (0.654, 0.896) |
| Oxygenation index | 0.808 | (0.697, 0.919) |
| SpO₂/FiO₂    | 0.830 | (0.721, 0.939) |
| Oxygen saturation index | 0.828 | (0.724, 0.932) |

5. Conclusions

Our study validates the prognostic power of the oxygenation indices PaO₂/FiO₂, SpO₂/FiO₂, OI, and OSI in severely ill COVID-19 patients. Early calculation of these simple metrics can help predict the clinical course of the patient’s disease, assist in prognostication, and guide therapeutic interventions.

Data Availability

The patient data used to support the findings of this study are restricted by the BMC and MGH Institutional Review Boards in order to protect patient privacy. Data are available from Drs. Nozari or Pinciroli for researchers who meet the criteria for access to confidential data.

Ethical Approval

This hospital registry study was approved by the Institutional Review Board at Boston Medical Center.

Consent

Consent was waived.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

SM and MV contributed to conception and design, data collection, analysis of data, and writing and revision of the manuscript. AG contributed to analysis of data, revision of the manuscript, and statistical expertise. AP and NF contributed to data collection and revision of the manuscript. RC, GR, RP, AN, and SQ contributed to analysis of data and revision of the manuscript. RO contributed to analysis of data and revision of the manuscript and provided administrative support. AN contributed to conception and design, analysis of data, writing and revision of the manuscript, and supervision.

Acknowledgments

The authors thank Mary Lukowsky and John Putzke of ScienceTRAX, LLC., for providing continuous technical support and granting the use of the StudyTRAX software free of charge. They also thank the departments of anesthesiology at each institution for providing research time to the investigators.

References

[1] R. B. Martines, J. M. Ritter, E. Matkovic et al., “Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States,” Emerging Infectious Diseases, vol. 26, no. 9, 2020.
[2] D. A. Berlin, R. M. Gulick, and F. J. Martinez, “Severe covid-19,” The New England Journal of Medicine, vol. 383, pp. 2451–2460, 2020.
[3] M. J. Cummings, M. R. Baldwin, D. Abrams et al., “Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York city: a prospective cohort study,” The Lancet, vol. 395, no. 10239, pp. 1763–1770, 2020.
[4] C. S. King, D. Sahjwani, A. W. Brown et al., “Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure,” PLoS One, vol. 15, no. 11, Article ID e0242651, 2020.
[5] M. Ackermann, S. E. Verleden, M. Kuehnel et al., “Pulmonary vascular endothelitis, thrombosis, and angiogenesis in covid-19,” New England Journal of Medicine, vol. 383, no. 2, pp. 120–128, 2020.
[6] R. Greene, S. Lind, H. Jantsch et al., “Pulmonary vascular obstruction in severe ARDS: angioraphic alterations after i.v. fibrinolytic therapy,” American Journal of Roentgenology, vol. 148, no. 3, pp. 501–508, 1987.
[7] L. Gattinoni, D. Chiumello, and S. Rossi, “COVID-19 pneumonia: ARDS or not?” Crit Care, vol. 24, no. 1, p. 154, 2020.
[8] A. D. T. Force, V. M. Ranieri, G. D. Rubenfeld et al., “Acute respiratory distress syndrome; the Berlin definition,” JAMA, vol. 307, no. 23, pp. 2526–2533, 2012.
[9] M. Van Haperen, P. Van der Voort, and R. Bosman, “The oxygenation index compared with the P/F ratio in ALI/ARDS,” Crit Care, vol. 16, p. 91, 2012.
[10] R. E. Dechert, P. K. Park, and R. H. Bartlett, “Evaluation of the oxygenation index in adult respiratory failure,” Journal of Trauma and Acute Care Surgery, vol. 76, no. 2, pp. 469–473, 2014.
[11] E. Seeley, D. F. McAuley, M. Eisner, M. Miletin, M. A. Matthey, and R. H. Kallet, “Predictors of mortality in acute lung injury during the era of lung protective ventilation,” Thorax, vol. 63, no. 11, pp. 994–998, 2008.
[12] H. K. Muniraman, A. Y. Song, R. Ramanathan et al., “Evaluation of oxygen saturation index compared with oxygenation index in neonates with hypoxemic respiratory failure,” JAMA Netw Open, vol. 2, no. 3, Article ID e191179, 2019.
[13] T. W. Rice, A. P. Wheeler, G. R. Bernard, D. L. Hayden, D. A. Schoenfeld, and L. B. Ware, “Comparison of the SpO₂/
FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS,” *Chest*, vol. 132, no. 2, pp. 410–417, 2007.

[14] W. Chen, D. R. Janz, C. M. Shaver, G. R. Bernard, J. A. Bastarache, and L. B. Ware, “Clinical characteristics and outcomes are similar in ARDS diagnosed by oxygen saturation/FIO2 ratio compared with PaO2/FIO2 ratio,” *Chest*, vol. 148, no. 6, pp. 1477–1483, 2015.

[15] K. DesPrez, J. B. McNeil, C. Wang, J. A. Bastarache, C. M. Shaver, and L. B. Ware, “Oxygenation saturation index predicts clinical outcomes in ARDS,” *Chest*, vol. 152, no. 6, pp. 1151–1158, 2017.

[16] S. B. Omer, P. Malani, and C. Del Rio, “The COVID-19 pandemic in the US: a clinical update,” *JAMA*, vol. 323, no. 18, pp. 1767–1768, 2020.

[17] F. Zhou, T. Yu, R. Du et al., “Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study,” *The Lancet*, vol. 395, no. 10229, pp. 1054–1062, 2020.

[18] M. Arentz, E. Yim, L. Klaff et al., “Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state,” *JAMA*, vol. 323, no. 16, pp. 1612–1614, 2020.

[19] X. Yang, Y. Yu, J. Xu et al., “Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study,” *The Lancet Respiratory Medicine*, vol. 8, no. 5, pp. 475–481, 2020.

[20] M. Parohan, S. Yaghoubi, A. Seraji, M. H. Javanbakht, P. Sarraf, and M. Djalali, “Risk factors for mortality in patients with coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies,” *The Aging Male: The Official Journal of the International Society for the Study of the Aging Male*, vol. 23, no. 5, pp. 1–9, 2020.

[21] L. B. Ware, “Prognostic determinants of acute respiratory distress syndrome in adults: impact on clinical trial design,” *Critical Care Medicine*, vol. 33, no. 3S, pp. S217–S222, 2005.

[22] O. Gajic, B. Afessa, B. T. Thompson et al., “Prediction of death and prolonged mechanical ventilation in acute lung injury,” *Critical Care*, vol. 11, no. 3, p. R53, 2007.

[23] G. Bellandi, J. G. Laffey, T. Pham et al., “Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries,” *JAMA*, vol. 315, no. 8, pp. 788–800, 2016.

[24] M. A. Matthay, R. L. Zemans, G. A. Zimmerman et al., “Acute respiratory distress syndrome,” *Nat Rev Dis Primers*, vol. 5, no. 1, p. 18, 2019.

[25] M. Monchi, F. Bellenfant, A. Cariou et al., “Early predictive factors of survival in the acute respiratory distress syndrome,” *American Journal of Respiratory and Critical Care Medicine*, vol. 158, no. 4, pp. 1076–1081, 1998.

[26] D. R. Ziehr, J. Alladina, C. R. Petri et al., “Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study,” *American Journal of Respiratory and Critical Care Medicine*, vol. 201, no. 12, pp. 1560–1564, 2020.